Streetbeat News

Equity Actions

TYRA

Tyra Biosciences, Inc. has announced a $200 million private placement financing. This significant financial infusion is aimed at bolstering the company's research and development efforts, potentially accelerating the development of its product pipeline.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:06 pm

GRI

GRI Bio has announced the pricing of a reasonable best efforts public offering, involving the participation of institutional investors. The offering consists of 5 million shares priced at $1.10 each.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 1:04 pm

GPN

Analysts have mixed views on Global Payments (NYSE:GPN), with ratings ranging from bullish to bearish. The average 12-month price target for GPN has increased to $150.86, up 10.28% from the previous target. The company shows strong profitability with a net margin of 14.62% but lags in ROE and ROA compared to industry benchmarks. Global Payments's market cap is below the industry average, indicating it's smaller than peers. The company's debt-to-equity ratio is healthy at 0.77.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:00 pm

CMS

CMS Energy (NYSE:CMS) received mixed analyst ratings with an updated average 12-month price target of $63.17, indicating a 5.28% increase from the previous target. Analysts from firms like Guggenheim, Barclays, and JP Morgan adjusted their ratings and price targets, reflecting a generally positive outlook. Despite facing revenue challenges with a -17.34% decline over 3 months, CMS Energy showcases strong profitability with notable net margin and ROE figures. However, its high debt-to-equity ratio raises financial leverage concerns.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:00 pm

CHTR

Charter Communications (CHTR) reported an increase in capital expenditures from $9.4 billion in 2022 to $11.1 billion in 2023, driven by its rural construction initiative and network expansion. The company anticipates further increasing its capex to between $12.2 billion and $12.4 billion in 2024, with significant investments in line extensions and network evolution.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 12:42 pm

CATX

EXFY

PCSA

RVP

Insiders are buying shares in four US-listed companies under $3: Retractable Technologies, Expensify, Perspective Therapeutics, and Processa Pharmaceuticals. These transactions indicate insider confidence in the companies' prospects. Retractable Technologies reported a loss, while Expensify received a price target upgrade. Perspective Therapeutics signed a licensing agreement, and Processa Pharmaceuticals announced a public offering.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 12:09 pm

BP

Kate Thomson has been officially appointed as the Chief Financial Officer (CFO) of BP and has joined the company's board with immediate effect. She has served as the interim CFO since September 2023.

Portfolio Pulse from Charles Gross

February 02, 2024 | 12:07 pm

HOLX

Analyst ratings for Hologic (NASDAQ:HOLX) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target is now $80.5, down from $83.50. Analysts from Needham, UBS, Morgan Stanley, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and Hologic's performance. Hologic, focusing on women's healthcare, faces challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 12:00 pm

META

Meta Platforms, Inc. (NASDAQ:META) shares surged over 16% in premarket trading following its Q4 earnings report, which exceeded expectations and surpassed Wall Street forecasts for key user metrics. The company also announced a quarterly dividend of 50 cents per share and a new $50 billion share repurchase authorization. KeyBanc Capital Markets analyst Justin Patterson reiterated an Overweight rating and increased the price target from $465 to $575, citing strong capital allocation and atypically strong 1Q guidance.

Portfolio Pulse from Shanthi Rexaline

February 02, 2024 | 10:46 am

HCM

HUTCHMED (China) Limited announced that Inmagene Biopharmaceuticals has exercised options to license two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership. HUTCHMED will receive approximately 7.5% of Inmagene's fully diluted shares in return for granting an exclusive license to Inmagene for the development, manufacturing, and commercialization of these candidates worldwide.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 8:35 am